Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
-
br Study limitations Although the number
2019-04-15
Study limitations Although the number of CPVT patients enrolled in the present study was small, we documented clearly discernible effects of flecainide on CPVT during exercise testing. The dose of flecainide was adjusted to increase it to the maximum tolerable dose without monitoring serum concen
-
We observed a downregulation of
2019-04-15
We observed a downregulation of several thyroid-related genes such as DUOX1, DUOX2, TG, and TSHR. This may appear counterintuitive given that dedifferentiation typically worsens patient outcomes. However, it is noteworthy that there was no difference in the SIRT1/2 Inhibitor IV of SLC5A5 (sodium-io
-
Hello world!
2018-07-29
15828 records 1056/1056 page Previous First page 上5页 1056